Clinical Trial Update: Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma

View source ↗

Summary

The trial update notes reports of peripheral neuropathy in patients treated with the enfortumab vedotin and pembrolizumab combination as first-line therapy for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Padcev (enfortumab vedotin)

Snippet

Sponsor: Comprehensive Cancer Center Munich (CCCM) | Conditions: Urothelial Cancer | Status: RECRUITING